CAS: 987-78-0; 2-(((((((2R,3S,4R,5R)-5-(4-Amino-2-Oxopyrimidin-1(2H)-yl)-3,4-Dihydroxytetrahydrofuran-2-yl)Methoxy)(Hydroxy)Phosphoryl)Oxy)Oxidophosphoryl)Oxy)-N,N,N-Trimethylethanaminium

上下游产品

trimethyl-(2-phosphono-ethyl)-ammonium cytidine monophosphate cytidine-5'-phosphodichloride alpha-D-glucopyranose2-oleoyl-1-palmitoyl-sn-glycero-3-phosph°Choline cytidine 5'-diphosph°Choline sodium salt

2',3'-O-Carbonylcytidin-5'-Phosphat 以 甲醇,水 作为反应溶剂,化学反应 25.0H,反应生成 胞二磷胆碱
参考文献:Cdp-Ethanolamine And Cdp-Choline: One-Pot Synthesis And 31P NMR Study
标题:Cdp-Ethanolamine And Cdp-Choline: One-Pot Synthesis And 31P NMR Study
摘要:
DOI:10.1016/j.Tetlet.2014.07.076

专利信息

专利号:US-8293290-B2
优先权日:2003-04-08
标题:Annatto extract compositions, including geranyl geraniols and methods of use
发明人：TAN BARRIE
权利人:TAN BARRIE; AMERICAN RIVER NUTRITION INC
摘要:Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.

专利号:US-10736912-B2
优先权日:2005-05-23
标 题 :Compositions containing PUFA and/or uridine and methods of use thereof
发明人：WURTMAN RICHARD; RICHARDSON INGRID
权利人:MASSACHUSETTS INSTITUE OF TECH; MASSACHUSETTS INST TECHNOLOGY
摘要:This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, and/or uridine, a metabolic precursor thereof, or a combination thereof.

专利号:US-6451568-B1
优先权日:1998-06-08
标 题:Cloning of human choline ethanolaminephospho transferases synthesis of phosphatidyl choline phosphatidyle thanolamine and platelet activating factor
发明人：MCMASTER CHRISTOPHER; HENNEBERRY ANETTE
权利人:UNIV DALHOUSIE
摘要:We report the first cloning and expression, from a mammalian source, of proteins capable of catalyzing choline- and ethanolaminephosphotransferase reactions (hCEPT1 and hCEPT2). Both coding regions predict highly hydrophobic proteins of 43-46.5 kDa with several predicted membrane spanning domains. A CDP-alcohol phosphotransferase motif, DG(x)2AR(x)8G(x)3D(x)3D, has been identified in both hCEPT1 and hCEPT2 choline- and ethanolamine-phosphotransferases (and several other lipid synthesizing enzymes that catalyze the formation of a phosphoester bond by the displacement of CMP from a CDP-alcohol by a second alcohol). Site-directed mutagenesis was used to differentiate the residues responsible for choline- versus ethanolamine-phosphotransferase activity. Mutation of glycine 156 of hCEPT1 abolished ethanolaminephosphotransferase activity, while cholinephosphotransferase activity remained intact.

专利号:US-5421733-A
优先权日:1989-04-28
标题 :Synthesis of Lex ; dimeric Lex (difucosyl Y2 ; III3 FucV3 FucnLc6 Cer); sialylated forms thereof; and analogues thereof
发明人：NUDELMAN EDWARD; SADOZAI KHALID K; CLAUSEN HENRIK; HAKOMORI SEN-ITIROH; STROUD MARK
权利人:BIOMEMBRANE INST
摘要:A process for preparing difucosyl Y2 antigen (dimeric Lex) , said process comprising: (1) preparing a lactonorhexaosylceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the III3 and V3 positions through an alpha 1->3 linkage. A process for preparing Ley antigen analogues, said process comprising: (1) preparing a lactonorhexaosyl-ceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the terminal beta -Gal through an alpha 1->2 linkage; and (3) enzymatically fucosylating said backbone at one or more positions through an alpha 1->3 linkage, provided that steps (2) and (3) can be conducted simultaneously or in any order. A process for preparing a fucosylated lactonorhexaosylceramide, lactonorhexaosylsaccharide linked to a carrier molecule or higher analogues thereof, said process comprising: (1) preparing a lactonorhexaosylceramide backbone, a lactonorhexaosylsaccharide backbone linked to a carrier molecule or backbones of higher analogues thereof; and (2) enzymatically fucosylating one or more residues of said backbone. A process for preparing sialyl Lex and sialyl dimeric Lex.

专利号:US-7429460-B2
优先权日:2003-01-15
标 题 :Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
发明人：FUTERMAN ANTHONY H; BODENNEC JACQUES; PELLED DORI
权利人:YEDA RES & DEV
摘要:The present invention discloses methods of screening for identification of compounds that inhibit novel targets in the enzymatic pathway of phospholipid synthesis that are related to glycolipid storage diseases, and use of the compounds for treating patients affected with glycolipid storage diseases, particularly Gaucher disease. Specifically, the compounds of the present invention are intended to inhibit the accumulation of phosphatidylcholine (PC), wherein PC accumulation is increased due to the activation of CTP:phosphocholine cytidylyltransferase (CCT) upon glucosylceramide (GlcCer) accumulation.

专利号:US-12083081-B2
优先权日:2021-04-29
标 题 :Sterile aqueous choline salt compositions
发明人：REARDAN DAYTON; ZUMMO JACQUELINE
权利人:PROTARA THERAPEUTICS INC
摘要:Disclosed are sterile aqueous choline salt compositions, their preparation, and methods of use. Also disclosed are methods to treat choline deficiency, intestinal failure associated liver disease (IFALD), and fatty liver disease. Additionally disclosed is a method of synthesis of choline salts.